Timely points of view from the people behind Bracken's work — on AI and clinical judgment, imaging endpoints, patient-focused development, and real-world evidence.
A polar “bullseye” chart that maps trial activity by therapeutic area, turning ClinicalTrials.gov data into an at-a-glance view of pipeline density, white space, and imminent readouts.
Read the Perspective
JL
BMThe Bracken GroupOperation TrialBlazer aims to make the U.S. the fastest place to start a trial. Here's what's in force, what is proposed, and what sponsors can do next.
The Bracken GroupA trial's imaging endpoint is a full measurement system, not a single scan. Here are the choices that drive data quality before the protocol locks.
CMReducing administrative delay shifts the burden to imaging endpoints as early go/no-go judgment becomes the binding constraint.
PMWith GLP-1 therapies, body composition, not the number on the scale, is the outcome that matters. Why DXA is emerging as the endpoint of choice.
MCPatient-focused drug development is now an expectation, not an aspiration. What it takes to embed the patient voice with genuine global vision.
CMAs AI reshapes how decisions get made, where does expert human judgment still matter most? A case for why the best advisory work is becoming more human, not less.
SMCMIs standardized uptake value the right metric for the earliest-phase trials? The case for alternative endpoints when the science demands precision.
MCReal-world data is changing how evidence is generated across the product lifecycle, but rigor still has to catch up in places.
Search 3,858 acronyms and terms for the field’s dense vocabulary.
Search the glossary84 core labs across 18 countries, filterable by type, region, and specialty.
Use the directoryTick off every section a clinical trial imaging charter should cover.
Get the checklistOur consultants bring these perspectives to real programs every day. Let's talk about yours.
Work with Bracken